海辰药业：2025年半年度净利润约2916万元，同比增加17.87%

Core Viewpoint - Haicheng Pharmaceutical reported a significant increase in both revenue and net profit for the first half of 2025, indicating strong financial performance and growth potential in the pharmaceutical industry [2] Financial Performance - The company's revenue for the first half of 2025 was approximately 309 million yuan, representing a year-on-year increase of 30.46% [2] - The net profit attributable to shareholders was around 29.16 million yuan, which is a year-on-year increase of 17.87% [2] - Basic earnings per share were 0.243 yuan, reflecting a year-on-year increase of 17.9% [2]